Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Next Previous
X
Search
Trial Profile

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tisagenlecleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms JULIET
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 12 Dec 2023 Results of analysis assessing impact of CAR persistence and B cell aplasia on duration of remission based on long term follow up data from pivotal phase II studies in patents with r/r ALL (ELIANA, ENSIGN, NCT03123939, NCT01626495), r/r DLBCL (JULIET), and r/r FL (ELARA), along with the long term follow up study (NCT02445222) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, focusing on Indirect comparisons therapeutic potential of epcoritamab as a novel, subcutaneous, off-the-shelf, core therapy for the treatments of patients with R/R LBCL in EPCORE NHL-1 and JULIETtrial.
    • 07 Dec 2023 According to a BostonGene media release, data from this trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top